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Abstract
Protein translocation between different subcellular compartments might play a significant role in various signal
transduction pathways. The S100 family is comprised of the multifunctional, small, acidic proteins, some of which
translocate in the form of vesicle-like structures upon increase in intracellular Ca2 levels. Previously, cells were fixed before
and after calcium activation in order to examine the possible relocation of S100 proteins. In this study, we were able to track
the real-time translocation. We compared the localization of endogenous S100A11 to that of the S100A11-green fluorescent
protein. The application of thapsigargin, an agent increasing intracellular Ca2 levels, resulted in the relocation of the
S100A11. In contrast, addition of EGTA, which specifically binds Ca2, either inhibited the ongoing process of translocation
or prevented its induction. Since translocation was not affected by treatment with brefeldin A, it appears that S100A11
relocates in an endoplasmic reticulum-Golgi-independent pathway. Furthermore, the depolymerization of actin filaments by
amlexanox did not affect the capacity of S100A11 to translocate. However, the time course treatment with demecolcine,
which depolymerizes tubulin filaments, resulted in cease of translocation, suggesting that the tubulin network is required for
this process. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
A growing number of studies suggest that S100
proteins are the possible e¡ectors in a variety of
physiological processes such as in£ammation, al-
lergy, or cancer [1^6]. The frequency of tumor-asso-
ciated rearrangement on the human chromosome
1q21, the region where most S100 genes cluster, has
led several research groups to examine and implicate
S100 proteins as possible markers in tumor grading.
Di¡erent S100 proteins are involved in speci¢c types
of cancers. For example, S100A4 induces metastasis
in breast cancer cells [7,8] and in non-small cell lung
cancer [9], while S100B is a marker for metastatic
melanoma [10,11]. In fact, the S100A11 might also
possess a substantial diagnostic value; it was re-
ported to be signi¢cantly overexpressed in colorectal
cancer, as compared to normal colorectal mucosa, or
in malignant melanomas of the uvea, with respect to
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normal uveal melanocytes [12^14]. Zhao and co-
workers showed that S100A11 inhibits actin-acti-
vated myosin ATPase activity [15]. Furthermore,
S100A11 is a component of the keratinocyte corni-
¢ed envelope [16,17], and it interacts with annexin-I
in a Ca2-dependent manner [18^20]. Recent studies
demonstrate the importance of Ca2 activation in
protein translocation [21^24]. Consequently, the pro-
cess of translocation may supply additional levels of
signaling control, by providing a rate-limiting step
with respect to induction of the cascades [25]. Anal-
ysis of expression levels, subcellular localization, and
the interactions with target proteins is essential in
establishing the speci¢c roles for di¡erent S100 pro-
teins. In order to study and characterize the potential
translocation of the S100A11, we have prepared
S100A11-green £uorescent fusion proteins and trans-
fected them into human glioblastoma cell lines,
which respond to thapsigargin with a Ca2 increase
and exhibit high levels of translocation. Previously,
green £uoroscent protein (GFP) was successfully
fused to other calcium binding proteins [26,27].
Modi¢ed for brighter £uorescence and higher expres-
sion in mammalian cells, it has become a great tool
for the monitoring of gene expression and protein
localization [28^30].
2. Materials and methods
2.1. Preparation of S100A11-GFP constructs
In order to fuse the S100A11 to GFP (enhanced
form, modi¢ed for brighter £uorescence, Clontech),
we designed primers which included a linker consist-
ing of ¢ve glycines, 20 bases of the S100A11-coding
sequence, and restriction sites compatible with the
GFP-containing vectors (XhoI-BamHI for pEGFP-
N1 or BglII-SalI for pEGFP-C1), followed by an
additional three bases. The primers were incorpo-
rated into S100A11 cDNA in the correct reading
frame by PCR. The modi¢ed sequences were di-
gested, puri¢ed, and ligated to the corresponding
vectors. DH5K were transformed with the aliquots
from the ligation mixtures. Plasmid DNA was puri-
¢ed from the resulting colonies, and the constructs
were analyzed by restriction digestion and DNA se-
quencing.
2.2. Cell culture
Human glioblastoma cell lines U-373MG and U-
87MG (HTB-17 and HTB-14, respectively, available
from ATCC) were maintained in 10% FCS-DMEM
with penicillin-streptomycin. The transfection of
GFP constructs was accomplished using the lipofect-
amine procedure. Cells were seeded at 2^2.5U105 per
35 mm well and incubated overnight. Plasmid DNA
(1 Wg) was added to DMEM (100 Wl). In a separate
tube, the lipofectamine (5 Wl) reagent (Life Technol-
ogies) was added to DMEM (100 Wl). These solutions
were combined and incubated for 15^30 min before
being diluted to 1 ml in DMEM and added to the
cells. After 5 h of incubation, a solution of 10% fetal
calf serum (FCS) in DMEM was added to each well
and cultures were incubated overnight. On the sec-
ond day, the transfection medium was changed to
the normal medium. Cells were either analyzed as
transient transfections or after they were submitted
to selection with G418.
The transfectants were maintained in the medium,
which additionally contained G418. They were pas-
saged at 80^90% con£uence. To examine localization
and translocation of the S100 endogenous and re-
combinant fusion proteins by confocal microscopy,
the cells (2^5U104) were plated on coverslips in
24-well dishes, 24 h prior to the experiment. The cells
to be stimulated were rinsed with DMEM, and then
incubated for 5^90 min with thapsigargin (100 nM^1
WM) in the stimulation bu¡er (140 mM NaCl, 5 mM
KCl, 1 mM MgCl2, 10 mM glucose, and 10 mM
HEPES, supplemented with 1 mM CaCl2) at 37‡C.
In order to assess the viability of cells after pro-
longed treatment with thapsigargin (Sigma), cells
(2.5U105) were seeded in 35 mm dishes (in tripli-
cate), incubated with thapsigargin for up to 90 min,
trypsinized, stained with trypan blue and counted.
In order to examine translocation of S100A11 in-
side live cells, 5^10U105 cells expressing fusion pro-
teins were seeded in 35 mm glass bottom dishes (Ma-
tek) and treated with di¡erent drugs. In order to
establish a time course for S100A11 translocation
following the application of thapsigargin, cells were
exposed to the drug while being monitored by micro-
scope time lapse photography. In order to determine
whether sequestering of Ca2 could inhibit the trans-
location, cells were incubated with 10 mM EGTA
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(which speci¢cally binds Ca2). A time course was
derived in order to establish at what point the po-
tential e¡ect occurs. In order to determine whether
the translocation of S100 proteins is linked to the
endoplasmic reticulum (ER)-Golgi-dependent path-
way, cells were treated with brefeldin A, which re-
versibly blocks this route (0.5^5 Wg/ml, Calbiochem),
and analyzed by microscope time lapse photography.
In order to resolve whether the relocation of S100
proteins is dependent on actin cytoskeleton or micro-
tubules, amlexanox (Takeda Chemical Industries),
which reversibly collapses actin stress ¢bers (1 WM),
or demecolcine (Sigma), which reversibly disrupts the
tubulin ¢laments (1 WM), was added to the cells.
Similarly, a time course was derived.
2.3. Immuno£uorescent staining
In order to stain cells with anti-S100A11, they
were rinsed with DMEM and ¢xed with 3.7% form-
aldehyde in DMEM for 15 min at 37‡C. Cells were
permeabilized with methanol for 10 min at room
temperature, washed in 5% horse serum (HS)-
DMEM, and incubated with a peptide anti-human
S100A11 (dilution 1/500), as described [31], for 1 h
at 37‡C. As a control, cells were incubated with the
antibodies pre-absorbed with S100A11 antigen. After
cells were washed twice for 5 min in 5% HS-DMEM,
they were incubated with Cy3-conjugated anti-rabbit
IgG (H+L) (goat, Jackson Immuno-Research Labo-
ratories) for 45 min at 37‡C. Cells were washed twice
for 5 min in 5% HS-DMEM, and once in PBS (pH
9).
The cells to be stained with the monoclonal Cy3-
conjugated anti-actin (mouse IgG2a isotype, recog-
nizes an epitope located at the C-terminus, which
is conserved in all actin isoforms, dilution 1/50, Sig-
ma) or anti-L-tubulin (mouse IgG1 isotype, localizes
L-tubulin in most species, including human, dilution
1/100, Sigma) were ¢xed with formaldehyde (3.7%
in PBS with Ca2/Mg2, at room temperature for
20^30 min) and washed twice with PBS. The ¢xed
cells were treated with NH4Cl (50 mM in PBS),
washed with PBS, and permeabilized with Triton
X-100 (0.1% in PBS) as described [32]. Cells were
incubated with antibodies against actin or tubulin
for 30 min and washed 4 times with PBS and once
with water.
In order to mount slides, a small drop of mounting
medium (Molviol, Hoechst) containing 0.75%
n-propyl-gallate as an anti-bleaching agent was
placed on the slide. Mounted slides were left to dry
for 24 h at room temperature and stored in the dark
at 4‡C until viewed.
2.4. Confocal laser scanning and wide-¢eld
microscopy
The samples with ¢xed cells were analyzed using a
Zeiss Axioplan £uorescence microscope (under 63U
oil objective lens) equipped with a confocal scanning
unit MRC-600 (Bio-Rad) and an argon-krypton laser
with an excitation wavelength of 568 nm for Cy3,
and 488 nm for enhanced GFP. Subsequently, the
images were processed using Graphic Converter (ver-
sion 3.8) and Photoshop (Adobe System, version 5.5)
software on a Macintosh computer.
The samples with live cells were analyzed by time
lapse photography, using a wide-¢eld Leica DM
IRBE microscope equipped with a Hamamatsu cam-
era controller (C4742-95) and connected to the Mac-
intosh computer. The imaging and recording were
operated by Open Lab software, version 2.1.1. The
25^50 images (depending on the quickness of the
cellular response) were recorded one every 4 s;
each exposure was set between 50 and 300 ms (de-
pending on the intensity of the signal, but constant in
each series) using a set ¢lter for GFP (Leica), and
neutral density ¢lters to minimize bleaching. The ob-
tained images were processed using Photoshop
(Adobe System, version 5.5) or converted into quick
time ¢les using a public domain NIH Image program
(developed at the US National Institutes of Health
and available on the Internet at http://rsb.info.nih.
gov/nih.-image/).
3. Results
3.1. S100A11-GFP constructs and their subcellular
localization
The modi¢ed S100A11 insert contained a ¢ve gly-
cine linker, which allowed for more rotational free-
dom between the S100A11 protein and GFP. The
S100A11 fused to the N-terminus of GFP (through
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Fig. 1. Preparation of S100A11-GFP constructs. S100A11 cDNA was modi¢ed by PCR and then ligated into the corresponding vec-
tor. (a) S100A11 was fused to the N-terminus of GFP, thus its stop codon was eliminated and the ¢ve glycine linker was added at
the 3P end. (b) S100A11 was fused to the C-terminus of the GFP, thus its start codon was removed and the ¢ve glycine linker was
added at the 5P end. Compatible restriction sites were added at the 5P and 3P ends of both primers, followed by an additional three
base pairs, which allowed for e⁄cient restriction digestion of the modi¢ed insert.
Fig. 2. Comparison of the localization of the endogenous S100A11 and the A11N or A11C fusion proteins in U-373MG cells. (a) Cells
were ¢xed and stained with anti-S100A11 and Cy3-conjugated goat anti-rabbit IgG (b: negative control, antibody pre-absorbed with
S100A11 antigen). (c,d) Cells were transfected with A11N construct (c) or with A11C construct (d). All samples were analyzed by la-
ser-scanning confocal microscopy.
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ligation to pEGFP-N1, Fig. 1a) was named A11N
and that to the C-terminus of GFP (through ligation
to pEGFP-C1, Fig. 1b) was named A11C. We trans-
fected the parental cells 6^7 times with the prepared
constructs. The transfection e⁄ciency was about
50^70%. The viability of transient transfectants was
s 90%. The experiments were performed within a
couple of days after transfection. Also, the transfec-
tants were selected and maintained in G418. The
Western blot of the total cell extracts showed that
the levels of endogenous S100A11 were una¡ected in
the transfectants. The expression of S100A11-GFP
fusion protein did not have a notable e¡ect on cell
growth rates or morphology. Transient and stable
transfectants gave similar results.
The localization of A11N and A11C was com-
pared to the endogenous expression. The untrans-
fected cells were ¢xed, stained with anti-S100A11
or the pre-absorbed antibody (Fig. 2a,b), and then
viewed by confocal microscopy. The cells transfected
with either construct were ¢xed and directly analyzed
(Fig. 2c,d). The staining of the fusion proteins was
similar to that of the endogenous S100A11 and
mostly appeared in the nucleus and perinuclear area.
3.2. S100A11 relocates in a Ca2+-dependent manner
In order to determine the e¡ects of intracellular
Ca2 increase, we stimulated cells for 10 min with
thapsigargin (0.5 WM, a non-phorbol ester, depleting
IP3-sensitive Ca2 stores of the ER, and thus increas-
ing cytosolic Ca2) [33^35]. Then we ¢xed and
stained cells with anti-S100A11 and the Cy3-conju-
gated secondary antibody. We observed vesicle-like
structures localized apart from where most of the
signal was concentrated. Scanning of the cell at the
di¡erent Z-levels using a confocal microscope re-
vealed that S100A11 was relocated toward the pe-
riphery of the cell (Fig. 3a^d). In order to verify
these events in real time, we seeded the A11N or
Fig. 3. Translocation of the S100A11 cells after thapsigargin treatment analyzed by confocal microscopy. The U-87MG cells were
treated for 10 min with 0.5 WM thapsigargin, followed by ¢xing and staining with anti-S100A11 and Cy3-conjugated anti-rabbit IgG.
The cell was laser scanned at di¡erent depths from cell top to cell bottom (a^d). The arrows point to the vesicles, which translocated
from the nucleus to the periphery of the cell.
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Fig. 4. Ca2-dependent S100A11 translocation cells analyzed by microscope time lapse photography. The U-87MG cells transfected
with A11N were seeded on glass bottom plates. After addition of thapsigargin (0.5 WM), a relocation of the S100A11 was observed al-
ready 1 min after treatment. In panel b (1.5 min) and c (2.5 min), formation and relocation of new vesicles are marked by arrows.
(d) A cell undergoing translocation is treated with 10 mM EGTA. (e) 1.5 min after addition of EGTA the size and the number of
vesicles sharply decreased. (f) 2.5 min after treatment any noticeable translocation ceased.
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A11C transfectants on the glass bottom plates and
viewed them using wide-¢eld microscopy. Most of
the experiments were performed using both con-
structs in the two cell lines (transient and stable
transfections), yielding very similar results. The ¢g-
ures shown are examples of the most representative
data.
Initial observation revealed that a small number of
the S100A11-GFP positive cells was undergoing
spontaneous S100A11 translocation. In fact, this
process would stop in one cell and begin in another
in 10^20% of the population at any time point. Ad-
dition of 0.5 WM thapsigargin, monitored by time
lapse (50 frames, one every 4 s), caused relocation
of S100A11 in 80^90% of the cells (within 1^2 min),
suggesting that this process occurs normally and can
be intensi¢ed by an increase in the intracellular Ca2
concentration (Fig. 4a^c).
The levels of total S100A11 (endogenous and fu-
sion proteins) were higher in the transfected cells, but
this did not a¡ect the translocation process. In un-
transfected cells stimulated with thapsigargin, we ob-
served formation and relocation of similar vesicles,
as in the cells transfected with the fusion protein.
Transient and stable transfectants gave similar re-
sults with respect to translocation. Viability of cells
after 0, 15, 45, and 90 min of treatment with 1 WM
thapsigargin assessed by staining of the triplicate
samples with trypan blue, showed on average no in-
crease in cell death. (Note that the concentration and
the length of treatment used for the viability test
were increased as compared to cell stimulation.)
When cells undergoing S100A11 translocation
were treated with 10 mM EGTA, which speci¢cally
chelates Ca2, the translocation process was com-
pletely inhibited within 2 min (Fig. 4d^f). There
was no decrease in cell viability after 60 min treat-
ment with EGTA. Although the initial Ca2 peak is
due to calcium release from the intracellular stores,
the continuous elevation in Ca2 levels requires Ca2
in£ux, which can be e¡ectively blocked by chelation
with EGTA [36^38]. In fact, Losavio and Muchnik
[39] found that EGTA or the permeant BAPTA
yielded similar overall results. Pretreatment of un-
stimulated cells with EGTA signi¢cantly reduced
the response of cells to thapsigargin; however, if
the EGTA-containing medium was replaced with
normal medium, cells resumed the process of trans-
Fig. 5. S100A11 translocation independent of the ER-Golgi
classical pathway. The U-373MG cells transfected with A11N
were seeded on glass bottom plates. After addition of brefeldin
A (5 Wg/ml) cells were monitored by microscope time lapse pho-
tography. After 45 min, cells were treated with thapsigargin (a^
c). The arrows show the formation or relocation of the vesicles
with respect to the previous frame.
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location (data not shown). Therefore, it appears that
the induction and the inhibition of translocation are
both Ca2-dependent and reversible.
3.3. Translocation of S100A11 is independent of the
ER-Golgi classical pathway
In order to determine whether the observed trans-
location depends on the ER-Golgi pathway, the cells
expressing fusion proteins were seeded on the glass
bottom plates and incubated with brefeldin A, which
blocks the classical translocation/secretion pathway.
After addition of up to 5 Wg/ml of brefeldin A
[40,41], cells were monitored by time lapse (50
frames, one every 4 s) at 15 min, 30 min, and
45 min, at which point the cells were treated with
0.5 WM thapsigargin (for selected frames see Fig.
5a^c). This led to an even more intensi¢ed activity.
A time course lasting for up to 2 h showed no in-
hibitory e¡ect on translocation.
3.4. S100A11 translocation depends on tubulin
network, but not on actin ¢lament
In an e¡ort to identify cellular components in-
volved in the process of translocation, the cells
were incubated with amlexanox [1], an anti-allergy
drug which reversibly depolymerizes actin cytoskele-
ton, or demecolcine, which reversibly depolymerizes
microtubules. We derived the time course guidelines
based on the depolymerization kinetics of actin or
tubulin ¢laments. We have treated cells with corre-
sponding drugs for di¡erent time periods (0, 30, 60,
and 120 min), ¢xed them, and analyzed them by
confocal microscopy. Untreated cells are shown in
Fig. 6a,c. Amlexanox had already a noticeable e¡ect
after 30 min, which was even more conspicuous after
60 min (Fig. 6b) and lasted trough 120 min. Deme-
colcine appeared to have a very pronounced e¡ect
after 30 min (Fig. 6d), which lasted for 60 min. How-
ever, the microtubules began to slowly re-polymerize
after 2 h.
We used cells undergoing spontaneous transloca-
tion to make this assessment more physiological. The
cells were treated with 1 WM amlexanox and re-
corded a time lapse (25 frames, one every 4 s) at
15 min, 45 min, and 120 min, at which point the cells
were also stimulated with thapsigargin (for selected
frames see Fig. 7a^c). Throughout the time course of
the experiment, the treatment of cells with amlexa-
Fig. 6. Amlexanox and demecolcine depolymerize actin and tubulin ¢laments, respectively. Cells were seeded on glass coverslips in a
24-well dish and left untreated (a,c) or incubated with 1 WM amlexanox for 60 min (b) or 1 WM demecolcine for 30 min (d). Then the
cells were ¢xed and stained with Cy3-conjugated anti-actin (a,b) or anti-tubulin (c,d). The samples were analyzed by confocal micros-
copy.
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nox had no noticeable e¡ect on S100A11 transloca-
tion. In order to accentuate the translocation we
added thapsigargin, which intensi¢ed the activity.
However, when cells undergoing translocation of
S100A11, monitored by time lapse (50 frames, one
every 4 s, for selected frames see Fig. 8a,b), were
incubated with 1 WM demecolcine, the process of
translocation was notably inhibited in less than
30 min (Fig. 8c). Furthermore, stimulation of cells
with thapsigargin at 45 min did not rescue cells (Fig.
8d^f). However, the removal of demecolcine would
result in restoration of the microtubules and trans-
location. Hence, the translocation of S100A11 specif-
ically requires tubulin ¢laments and is independent
of the actin cytoskeleton or cell shape.
4. Discussion
The indisputable relationship between the deregu-
lated expression of S100 proteins and cancer, Alz-
heimer’s disease, or in£ammation strongly suggests
their profound involvement in these processes [1^6].
However, despite the overwhelming correlation be-
tween the S100 proteins and di¡erent pathological
processes, many questions remain unanswered.
Hence, the analysis of the cellular processes in which
they are involved should provide a step toward de-
picting their signaling pathways. Previously, in order
to examine possible relocation of the S100 proteins,
cells were ¢xed before and after calcium activation,
o¡ering limited £exibility with respect to drug ma-
nipulation and con¢ning analysis to the general ef-
fects on the cell population. Our system allows for
tracking of the real-time translocation and determin-
ing the outcome produced by di¡erent drugs in the
same cell.
We have found that reversible translocation oc-
curred in unstimulated glioblastoma cells which al-
ready exhibit high Ca2 levels, suggesting that
unknown Ca2 triggers regulate subcellular localiza-
tion of S100A11 at di¡erent times. However, thapsi-
gargin, which increases cytosolic Ca2, e¡ectively in-
duced or intensi¢ed this process, con¢rming earlier
¢ndings [22,23]. These results are supported by the
reversal of translocation by EGTA, a speci¢c Ca2
chelator. The fact that in resting cells S100 proteins
are localized to the speci¢c cellular compartments
Fig. 7. S100A11 translocation is independent of actin ¢laments.
The U-87MG cells transfected with A11N were seeded on glass
bottom plates, treated with 1 WM amlexanox and monitored by
microscope time lapse photography. At 120 min, cells were
stimulated with 0.5 WM thapsigargin (a). (b) A cell treated for
1.5 min. (c) A cell was incubated for 3 min. Arrows mark the
change in vesicle formation.
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Fig. 8. Tubulin-dependent S100A11 translocation. U-87MG cells transfected with A11N were seeded on glass bottom plates, treated
with demecolcine (1 WM), and monitored by microscope time lapse photography. The di¡erences in vesicle appearance between panel
a (directly after addition of the drug) and panel b (1.5 min later) are marked by arrows. Panel c shows the disappearance of translo-
cation after 30 min. (d) Cells were stimulated with thapsigargin (0.5 WM), which did not induce translocation 1.5 min later (e) or
3 min later (f).
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from which they relocate upon Ca2 activation sug-
gests that the translocation might be the key mecha-
nism in the assembly of signaling complexes, regulat-
ing it in a temporal and spatial manner. Ca2-
dependent association and targeting of S100A11 to
early endosomes by annexin I [18^20] could feasibly
depend on translocation. Similarly, the Ca2-depen-
dent inhibition of actin-activated myosin ATPase [15]
might be linked to S100A11 relocation.
Considering that Ca2 homeostasis is often
a¡ected in cancer cells, it is not surprising that
Ca2-binding S100 proteins may serve as vehicles
for abnormal Ca2 signaling. Perhaps the anomalous
(or poorly timed) elevation of Ca2 concentration
could lead to the increased translocation of the
S100 proteins and the undesired interaction with
target proteins, which in turn may potentiate the
pathological condition. The scheme presented by
Meyer and Shen [25], in which translocation in nor-
mal cells provides ¢ne tuning to the signaling cas-
cades, supports this model. The regulation of the
number of signaling proteins at one site by a con-
trolled release from another site prevents formation
of signaling complexes in the absence of su⁄cient
stimulus.
On the other hand, the observed translocation
seems to occur in a distinct manner. Brefeldin A,
which blocks the classical ER-Golgi secretion path-
way, does not seem to have any e¡ect on the trans-
location of S100A11, which is in agreement with
Rammes et al. [40] reporting that S100A8/A9 are
secreted independently of this route. This would be
expected since S100 proteins lack a signal sequence
for secretion via the classical pathway. In an attempt
to identify the cellular components involved in the
translocation of S100A11, we have collapsed the ac-
tin cytoskeleton or tubulin network. The depolymer-
ization of actin ¢laments did not inhibit S100A11
translocation. In fact, Sakaguchi et al. showed that
dissociation of S100A11 from actin is a prerequisite
for its transport to the nucleus [42]. However, the
microtubules were essential for this process. Roth
and co-workers [40] have demonstrated the involve-
ment of microtubules in the secretion of the S100A8/
A9, while Donato’s group has shown a co-localiza-
tion of S100B and microtubules [43] and the possible
S100B-mediated disassembly of tubulin in situ [44].
Combining these results suggests that the tubulin
network might be the primary component interacting
with the S100 proteins, which regulates their trans-
location, implying a novel route, possibly related to
the alternative secretion pathway utilized by cyto-
kines [45].
Moreover, phosphorylation of S100 proteins ap-
pears to be another mechanism regulating these pro-
teins. Vogl et al. [46] found that S100A9 through
phosphorylation by MAP kinase p38 might control
monocyte transmigration. A recent report by Saka-
guchi et al. suggests that in normal con£uent cells the
S100A11 becomes phosphorylated on Thr 10, disso-
ciates from actin ¢laments, and becomes translocated
to the nucleus, where it upregulates p21 and p16
leading to growth arrest. They found that phosphor-
ylation was required for nuclear transport, but it was
not necessary for growth inhibition. Although they
reported that in immortalized cells, which they exam-
ined, S100A11 was not phosphorylated or trans-
ported to the nucleus, we found high levels of
S100A11 in the nuclear and perinuclear areas of
the glioblastoma cells. Furthermore, earlier studies
have shown overexpression of S100A11 in colorectal
cancer and ocular melanoma [12^14]. Perhaps, one
way to resolve these seemingly con£icting results is to
view the S100A11-mediated growth arrest as a multi-
step process in which S100A11 phosphorylation/
translocation is one of the many points that can be
targeted in cellular transformation. Conceivably, in
some transformed cells, S100A11 can still be trans-
located to the nucleus, but another signal contribut-
ing to induction of p16 and p21 expression is absent.
In fact, the cell may attempt without success to com-
pensate for lack of contact inhibition by upregulating
the S100A11 expression, as shown in di¡erent can-
cers. On the other hand, S100A11 could have several
di¡erent functions. For example, another member of
the S100 family, S100B, was found to be a glial mi-
togen, but under special conditions it can induce ap-
optosis. In fact, S100B was recently reported to in-
teract with S100A11 in a manner similar to those of
target proteins [47]. Furthermore, the observed local-
ization of vesicles containing S100A11 at the cell
membrane implies the possibility of secretion.
Although this is not certain, the recent discovery of
RAGE, a receptor for S100A12 and S100B [2], sup-
ports the extracellular role for the S100 protein fam-
ily.
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